
Dr. Reddy’s denies report of 25% workforce cost cut amid Revlimid margin strain
Dr. Reddy’s Laboratories Ltd. has firmly denied a recent media report alleging that the company has cut workforce costs by 25% amid margin pressure linked to Revlimid. In a regulatory filing to the stock exchanges dated April 14, 2025, the pharmaceutical …